<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01776697</url>
  </required_header>
  <id_info>
    <org_study_id>DW330SR-1001(Ver2.2)</org_study_id>
    <nct_id>NCT01776697</nct_id>
  </id_info>
  <brief_title>Phase 1 Study to Compare the Pharmacokinetic Characteristics and Food Effect of Pelubiprofen (30mg) Tablet IR TID and Pelubiprofen SR (as a Pelubiprofen 90 mg) Tablet QD in Healthy Subjects</brief_title>
  <official_title>A Randomized, Open-labeled, Comparative 3-way Crossover Study to Compare the Pharmacokinetic Characteristics and Food Effect of Pelubiprofen (30mg) Tablet IR TID and Pelubiprofen SR (as a Pelubiprofen 90 mg) Tablet QD in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewon Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daewon Pharmaceutical Co., Ltd.</source>
  <brief_summary>
    <textblock>
      A randomized, open-labeled, comparative 3-way crossover study to compare the pharmacokinetic
      characteristics and food effect of pelubiprofen (30mg) tablet IR TID and pelubiprofen SR (as
      a pelubiprofen 90 mg) tablet QD in healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>AUC of pelubiprofen(30mg) tablet IR TID</measure>
    <time_frame>0, 1, 2, 8, 9, 15, 16, 22 day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC of pelubiprofen SR (as a pelubiprofen 90 mg) tablet QD</measure>
    <time_frame>0, 1, 2, 8, 9, 15, 16, 22 day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of pelubiprofen(30mg) tablet IR TID</measure>
    <time_frame>0, 1, 2, 8, 9, 15, 16, 22 day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of pelubiprofen SR (as a pelubiprofen 90 mg) tablet QD</measure>
    <time_frame>0, 1, 2, 8, 9, 15, 16, 22 day</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>pelubiprofen (30mg) tablet IR TID, fasting</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>pelubiprofen (30mg) tablet IR TID, fed</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>pelubiprofen SR (as a pelubiprofen 90 mg) tablet QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pelubiprofen (30mg) tablet IR</intervention_name>
    <arm_group_label>pelubiprofen (30mg) tablet IR TID, fasting</arm_group_label>
    <arm_group_label>pelubiprofen (30mg) tablet IR TID, fed</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pelubiprofen SR (as a pelubiprofen 90 mg) tablet</intervention_name>
    <arm_group_label>pelubiprofen SR (as a pelubiprofen 90 mg) tablet QD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult Healthy males aged 20~45 years

          2. weight over 45 kg, ideal body weight Â±20%[Ideal weight] = [Height(cm)-100] X 0.9

          3. Subjects who voluntarily agreed with written consent

        Exclusion Criteria:

          1. Patients with acute disorder within 28 days before clinical trial drugs administration

          2. History of disorders(inflammatory GI tract disease, stomach ulcer, gastrectomy, liver
             disease) which can affect ADME of drugs

          3. Patients with active GI tract, cardiovascular, respiratory, renal, endocrinal,
             haematological, central nerval, psychiatric disease or malignant tumor
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 22, 2013</study_first_submitted>
  <study_first_submitted_qc>January 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2013</study_first_posted>
  <last_update_submitted>January 23, 2013</last_update_submitted>
  <last_update_submitted_qc>January 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

